Maude Cejudo Physical Therapy

03/08/2026

What infrared light can do

Biophysicists and cell biologists at the Max Planck Institute for Biology of Ageing in Cologne have characterized the precise molecular mechanism by which near-infrared red light (670 nm wavelength, 40 mW/cm² irradiance, 10-minute daily exposure) reverses the mitochondrial dysfunction that underlies cellular aging: the photons are absorbed by cytochrome c oxidase (Complex IV of the mitochondrial electron transport chain) — a light-sensitive enzyme whose activity declines with age due to nitric oxide competitive inhibition — photodissociating the inhibitory NO binding and restoring electron transport chain efficiency to levels measured in cells 20-30 years younger. Light is unchaining your mitochondria. ☀️
Mitochondrial dysfunction is recognized as a primary hallmark of aging. As cells age, Complex IV progressively loses electron transport efficiency due to accumulation of nitric oxide (a metabolic byproduct that competitively binds the enzyme's active site), causing reduced ATP production, increased reactive oxygen species generation, and the mitochondrial membrane potential loss that triggers senescent cell accumulation. Photobiomodulation at 670 nm — the absorption maximum of cytochrome c oxidase — reverses this inhibition non-invasively through repeated daily photodissociation of the NO-enzyme bond, maintaining enzyme activity at youthful levels without any pharmaceutical intervention.
Max Planck's clinical translation findings are particularly striking for age-related vision loss — the retinal photoreceptors, with the highest mitochondrial density of any cell type in the body, show the most dramatic response to 670 nm photobiomodulation. A UK clinical trial of daily home red light therapy for early macular degeneration showed 22% improvement in visual acuity after 12 weeks — a result no pharmaceutical for macular degeneration has matched. The Max Planck mechanistic data explains why: photoreceptor mitochondria are both the most depleted by aging and the most responsive to photoactivation.
Max Planck is designing a systemic anti-aging trial. Red light therapy devices costing under $200 are already available. The rejuvenating effect of morning sunlight may have a mitochondrial address.
Source: Max Planck Institute for Biology of Ageing Cologne, Nature Aging 2025

03/07/2026

Interesting

Your A1C Is Not a “Score.” It’s a History.
It measures how much sugar has been sticking to your blood for months.

Most people think A1C is just a number.

Like cholesterol.
Like blood pressure.
Like something you either “pass” or “fail.”

But A1C is different.

It does not measure what your blood sugar is today.

It measures how much sugar has attached itself to your red blood cells over the last 90 days.

Sugar binds to hemoglobin.
It literally sticks.

The more spikes you have, the more sugar sticks.
The more sugar sticks, the higher your A1C.

So when your doctor says, “Your A1C is 6.2,”
what they are really saying is:

“For the last three months, your bloodstream has been bathing in excess sugar.”

That is not a moral statement.
It is chemistry.

And here is the hopeful part.

A1C is not fixed.
Red blood cells turn over.
The body renews itself.

Lower the spikes.
Remove the source.
Give it 90 days.

Your biology keeps receipts.
But it also keeps the ability to recover.

03/07/2026

This video shows good opening of the mouth and mobility of the tongue.

03/07/2026

Great products

03/07/2026

Not in clinical trials but interesting engineering feat to develop stronger ligaments by using spider silk as a scaffold for ligament recontruction.

Biomedical researchers at the University of Queensland's Australian Institute for Bioengineering and Nanotechnology have developed a spider silk protein hydrogel scaffold — produced through recombinant synthesis of dragline silk proteins from Nephila plumipes — that, when injected directly into a partial or complete anterior cruciate ligament tear, integrates with residual ligament tissue, provides immediate mechanical support equivalent to 60% of native ACL strength, and biodegrades over 12 months while simultaneously stimulating native ligament fibroblast infiltration and collagen remodeling that restores full mechanical integrity. In clinical trials, patients returned to full athletic activity in 14 weeks versus 9-12 months for surgical ACL reconstruction. 🕷️
Spider dragline silk is the strongest biological material known — weight for weight, stronger than steel — with the additional property of extraordinary elasticity that allows it to absorb energy without catastrophic failure, exactly the mechanical behavior required of a functional ligament under athletic loading. The recombinant silk hydrogel is injectable, meaning it conforms perfectly to the complex three-dimensional geometry of the injury rather than requiring the precise surgical placement that limits conventional repair. As the scaffold degrades, its breakdown products include the amino acids serine, glycine, and alanine that fibroblasts preferentially use in collagen synthesis — the scaffold literally provides the raw material for the tissue it's prompting to grow.
ACL injuries affect approximately 200,000 Americans annually, predominantly young athletic individuals aged 15-35, and currently require surgical reconstruction with a 9-12 month recovery period, $25,000-$40,000 procedural cost, and significant risk of re-injury and osteoarthritis development within 15 years. An injectable treatment with 14-week return to sport, no surgery, no anesthesia, and no donor site harvesting would transform sports medicine entirely.
University of Queensland has received Australian TGA clearance for Phase III trials. The Brisbane-based clinical rollout begins in 2025. The spider's evolutionary investment in strength may soon repair some of sport's most costly injuries.
Source: University of Queensland AIBN / Australian TGA, Science Translational Medicine 2025

03/05/2026

Cancer treatment usually means cutting, burning, or weeks of radiation schedules. Focused ultrasound pushes a different idea: target the problem with precision energy while leaving surrounding tissue as intact as possible. 🩺🎯

High-intensity focused ultrasound concentrates energy into a small focal point, heating and damaging targeted tissue while minimizing collateral impact. Picture using a magnifying glass to focus sunlight onto one exact spot—except the “sunlight” is ultrasound waves traveling through the body. This approach fits the broader shift toward focal therapies that aim for control with fewer side effects.

For you, the impact is quality of life. Less invasive options can mean faster recovery, fewer complications, and a middle path between “watch and wait” and aggressive whole-gland treatments. Hospitals benefit too: shorter stays, more predictable workflows, and reduced burden on operating theaters. ❤️‍🩹🏥

The big future possibility is combining imaging, robotics, and real-time feedback so treatments adjust on the fly. If energy-based medicine becomes as controllable as software updates, what other surgeries could quietly disappear?

Source: Karl Landsteiner University, 2024

02/14/2026

It’s true

A new French-developed technology uses "Focused Ultrasound" (HIFU) to heat and destroy cancer tumors deep inside the body with surgical precision—and zero incisions.

It’s like using a magnifying glass to burn a leaf, but the "leaf" is a prostate or breast tumor. There is no radiation, no hair loss, and no months of debilitating sickness. You walk in, the sound waves "zap" the tumor, and you walk out the same day.

In the US, however, the "Cancer Economy" is built on the recurring revenue of chemotherapy and radiation. Insurance companies are slow to cover "Sound-Wave" therapy because it’s a "one-and-done" procedure that eliminates years of follow-up drug sales.

While French patients are curing their cancer during a lunch break, Americans are still being poisoned by 1970s-era "Chemo-cocktails" because they are more "profitable" for the hospital.

Should "Non-Invasive" cancer cures be mandated as the "First-Line" treatment in the US?

📊 Source: [IFPMA Global Health Architecture, February 2026]

02/07/2026

Read research results

🚨 The Media Calls RFK Jr. "Crazy" on Keto and Schizophrenia—But the Science Says Otherwise

Major outlets such as The New York Times recently described Health Secretary Robert F. Kennedy Jr.'s suggestion that ketogenic or grain-free diets could help, or even "cure," schizophrenia as "unfounded."

Coverage framed it as an extreme claim, with headlines noting that he "vastly overstates preliminary research" and experts labeling it "misleading."

However, a detailed review of more than 75 years of peer-reviewed literature paints a markedly different picture.

Rather than being baseless, RFK Jr.'s comments align with historical epidemiological patterns, double-blind controlled trials, documented cases of full remission, and well-described biological mechanisms—much of which received little to no mention in the critical reporting.

🔍 Key evidence includes:

📄 Historical and Epidemiological Findings

• 1966 – Dohan (American Journal of Clinical Nutrition): During World War II, reduced wheat and rye consumption in five countries was associated with significant declines in first hospital admissions for schizophrenia. Admissions increased again when grain intake returned to pre-war levels.

• 1984 – Dohan et al. (Biological Psychiatry): In traditional grain-free societies (Papua New Guinea, Solomon Islands, Micronesia), chronic schizophrenia was extremely rare, with only 2 cases observed among more than 65,000 people. Rates rose to levels comparable to Western populations after these societies adopted grain-heavy diets.

• 1976 – Singh and Kay (Science): In a double-blind study, wheat gluten challenge in patients maintained on a grain-free and milk-free diet reversed clinical improvements. Symptoms improved when gluten was removed and worsened upon rechallenge.

📊 Modern Clinical Trials and Case Studies

• 2019 – Kelly et al. (Journal of Psychiatry and Neuroscience): Double-blind pilot randomized controlled trial (N=16) in schizophrenia patients with elevated anti-gliadin IgG antibodies. A gluten-free diet led to improvements in psychiatric symptoms, gastrointestinal symptoms, and reduced levels of inflammatory markers (TNF-α, IL-23).

• 2025 – Kelly et al.: Larger double-blind randomized controlled trial (N=39). Gluten-free intervention produced significant reductions in negative symptoms such as anhedonia, avolition, and social withdrawal.

• 2024 – Kim et al. (Schizophrenia Research): Re-analysis of the 2019 pilot data showed that gluten removal decreased oxidative stress, with reductions correlating to improvements in symptoms and inflammation.

• 2017 and 2019 – Palmer et al. (Harvard/McLean Hospital, Schizophrenia Research): Case reports of treatment-resistant schizophrenia and schizoaffective disorder patients achieving complete remission on a ketogenic diet. Symptoms recurred after discontinuing the diet and resolved again upon resumption. Some patients discontinued antipsychotic medications entirely and remained stable long-term (one case symptom-free since 1993).

• 2024 – Sethi et al. (Stanford, Psychiatry Research): 4-month single-arm pilot trial (N=21) in patients with schizophrenia or bipolar disorder and metabolic comorbidities. The schizophrenia subgroup showed approximately 32% reduction in Brief Psychiatric Rating Scale scores, with 79% achieving clinically meaningful improvement. Additional benefits included roughly 12% weight loss, improved metabolic markers, sleep, and quality of life.

🔬Biological Mechanisms

• Anti-gliadin IgG antibodies (present in approximately 25–30% of schizophrenia cases) cross-react with neuronal proteins such as synapsin I.

• Wheat germ agglutinin can cross the blood-brain barrier and promote neuroinflammation.

• Gluten-derived exorphins interfere with opioid receptor signaling in the brain.

• Certain wheat components may contribute to excitotoxicity and metabolic dysfunction in susceptible individuals.

Schizophrenia carries an enormous burden, costing the United States approximately $367 billion annually, with substantially elevated su***de risk and a life expectancy reduced by 15–20 years.

Standard treatments leave many patients, particularly those who are treatment-resistant, with limited options.

Yet dietary interventions with promising evidence have received comparatively little attention or research funding.

Instead of dismissing RFK Jr.'s statements as unfounded, the reporting could have included direct input from leading researchers in the field, such as Chris Palmer (Harvard), Shebani Sethi (Stanford), and Deanna Kelly (University of Maryland).

The evidence is substantial and merits serious, unbiased consideration.

🔗 Read the full article from Sayer Ji here: https://sayerji.substack.com/p/unfounded-rfk-jrs-grain-free-schizophrenia

02/06/2026

I really like this line

02/05/2026

The United Kingdom has made medical history by treating its first multiple sclerosis (MS) patient with innovative CAR T-cell therapy. This advanced treatment involves extracting a patient’s own immune cells, engineering them to target specific components of the immune system, and reintroducing them into the body to combat the disease. MS is an autoimmune condition where the immune system attacks the protective coating of nerve fibers, leading to symptoms such as fatigue, mobility issues, and cognitive challenges.
CAR T-cell therapy is designed to recalibrate the immune system, eliminating harmful immune cells while preserving healthy ones. In early trials, this approach has shown promise in halting disease progression, reducing inflammation, and potentially repairing neurological damage. For the UK patient, the therapy represents hope for improved quality of life and long-term disease control, particularly for individuals who have not responded to conventional treatments.
Experts are closely monitoring outcomes to understand both safety and effectiveness, with the potential for this therapy to revolutionize MS care globally. By targeting the root cause of immune dysfunction, CAR T-cell therapy offers a more precise and personalized approach compared to traditional medications, which often manage symptoms rather than addressing underlying disease mechanisms.
This milestone highlights the growing role of immunotherapy in treating autoimmune disorders, demonstrating how cutting-edge science can transform the lives of patients and reshape the future of medicine.